Gefitinib (also known as Iressa or ZD1839) is an epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI) widely used to treat advanced non-small cell lung cancer (NSCLC) [4]. The gene discussed is EGF; the disease is non-small cell lung carcinoma.